Comparative Pharmacology
Head-to-head clinical analysis: KRYSTEXXA versus ZURAMPIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KRYSTEXXA versus ZURAMPIC.
KRYSTEXXA vs ZURAMPIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KRYSTEXXA (pegloticase) is a recombinant uricase enzyme conjugated to polyethylene glycol (PEG) that catalyzes the oxidation of uric acid to allantoin, thereby lowering serum uric acid levels. Allantoin is a more water-soluble metabolite that is readily excreted by the kidneys.
Selective inhibitor of URAT1 (uric acid transporter 1) and OAT4 (organic anion transporter 4), increasing uric acid excretion and reducing serum uric acid levels.
8 mg intravenously every 2 weeks.
200 mg orally once daily.
None Documented
None Documented
Terminal half-life: 10–15 days in patients with chronic gout; prolonged due to immunogenicity and target-mediated drug disposition.
Terminal elimination half-life is approximately 5 hours; clinically, this supports twice-daily dosing.
Renal: negligible (<1% unchanged); metabolism via proteolysis to small peptides and amino acids; no biliary/fecal elimination quantified.
Primarily renal (approximately 70% unchanged in urine), with minor biliary/fecal excretion (less than 10%).
Category C
Category C
Uric Acid Lowering Agent
Uric Acid Lowering Agent